About Javeri
Product & Services
Equity
Derivatives
Mutual Funds
IPO
Corporate Info
Research
Contact Us
Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME
>
CORPORATE INFO
>
BOARD MEETINGS
Board
Meetings
Torrent Pharmaceuticals Ltd.
From Date
:
To Date
:
Source Date
Board Meeting Date
Details
10-Oct-2024
25-Oct-2024
Quarterly Results
05-Jul-2024
23-Jul-2024
Quarterly Results
10-May-2024
24-May-2024
Final Dividend & Audited Results
12-Jan-2024
02-Feb-2024
Quarterly Results & Interim Dividend
09-Oct-2023
23-Oct-2023
Quarterly Results
17-Jul-2023
07-Aug-2023
Quarterly Results
16-May-2023
30-May-2023
Final Dividend & Audited Results
12-Jan-2023
25-Jan-2023
Quarterly Results & Interim Dividend
04-Oct-2022
21-Oct-2022
Quarterly Results
11-Jul-2022
29-Jul-2022
Quarterly Results
06-May-2022
25-May-2022
Final Dividend & Bonus issue & Audited Results
10-Jan-2022
25-Jan-2022
Quarterly Results & Interim Dividend
11-Oct-2021
26-Oct-2021
Quarterly Results
09-Jul-2021
27-Jul-2021
Quarterly Results
28-Apr-2021
18-May-2021
Audited Results & Final Dividend Inter alia, the Board would also consider the following: i. Payment of Final Dividend for the year 2020-21. ii. Taking enabling resolutions for raising of funds by issue of Equity Shares including Convertible Bonds / Debentures through Qualified Institutional Placement (QIP) and / or Depository Receipts or any other modes. If approved by the Board of Directors, the said item will be placed for Shareholders' approval in the ensuing Annual General Meetin
18-Jan-2021
08-Feb-2021
Interim Dividend & Quarterly Results
13-Oct-2020
26-Oct-2020
Quarterly Results
14-Jul-2020
30-Jul-2020
Quarterly Results
18-May-2020
26-May-2020
Audited Results
03-Mar-2020
11-Mar-2020
TORRENT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/03/2020 ,inter alia, to consider and approve We would like to inform you that a meeting of the Board of Directors of the Company will be held on Wednesday, 11th March, 2020 to consider the proposal for payment of Interim Dividend for the year 2019-20.
Page
1
of
5
Prev
||
Next
Disclaimer
|
Privacy Policy
| Grievance |
FAQ
|
Sitemap |
Client Registration |
Useful Links
|
Anti Money Laundering
|
Inactive Client Policy
|
Scores
Vernacular Kyc
|
Advisory For Investors
|
Investor Adviser
|
Filing complaints on SCORES - Easy & quick
|
Policy on PMLA
Publishing of investor charter information
|
Annexure A – Investor charter of brokers
|
Annexure A – Investor charter of DP
|
Annexure B –Linked content for information to charter for DP
|
Annexure B & C (investor complaint data) broker & DP
Investor Charter & Complaints
|
Advisory-KYC Compliance
|
E-Voting NSE
|
E-Voting BSE
|
Details of Client Bank Accounts
|
Risk Disclosure
|
NSE FO Risk disclosure
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by
Accord Fintech Pvt. Ltd.
CLOSE
X
RISK DISCLOSURES ON DERIVATIVES
9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source:
Click Here.